Novabiotics - a leading clinical-stage biotechnology company
Novabiotics about us Novabiotics clinical studies Novabiotics pipeline Novabiotics our news Novabiotics contact

NP339 for Invasive Fungal Disease

For life-threatening fungal disease in immunocompromised patients.


Patients with compromised immunity lack critical endogenous defense systems which protect them against potentially life threatening fungal infections.


NP339 has been designed to temporarily restore these defenses. It is an antifungal peptide with rapid, fungicidal activity against a broad range of clinically relevant pathogens including Aspergillus spp., Candida spp., Cyptococcus spp. as well as emerging, rare and drug-resistant organisms such as Mucorales and Candida auris. NP339 has a resistance-mitigating mechanism of action and toxicity profile that is highly distinct from other classes of antifungal, both in clinical use and development, because it is based on immune defense molecules.

Link to our peer reviewed article “Preliminary Characterisation of NP339, a Novel Polyarginine Peptide with Broad Antifungal Activity” ASM Article [opens in new window]